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ABSTRACT: The trace amine-associated receptor 1
(TAAR1) is a G-protein-coupled receptors (GPCR) potently
activated by a variety of molecules besides trace amines (TAs),
including thyroid hormone-derivatives like 3-iodothyronamine
(T1AM), catechol-O-methyltransferase products like 3-me-
thoxytyramine, and amphetamine-related compounds. Accord-
ingly, TAAR1 is considered a promising target for medicinal
development. To gain more insights into TAAR1 physiological
functions and validation of its therapeutic potential, we
recently developed a new class of thyronamine-like derivatives.
Among them compound SG2 showed high affinity and potent
agonist activity at mouse TAAR1. In the present work, we
describe design, synthesis, and SAR study of a new series of compounds (1−16) obtained by introducing specific structural
changes at key points of our lead compound SG2 skeleton. Five of the newly synthesized compounds displayed mTAAR1 agonist
activity higher than both SG2 and T1AM. Selected diphenylmethane analogues, namely 1 and 2, showed potent functional
activity in in vitro and in vivo models.
■ INTRODUCTION
Thyronamine (TAM) is generally used to indicate a class of
endogenous compounds deriving from thyroid hormones
through metabolic reactions such as deiodination and
decarboxylation.1 Over the past decade, thyronamines have
been recognized as ligands of trace amine associated receptor 1
(TAAR1), and to date they represent a thriving research field.
Currently, only two compounds that belong to the class of
TAM have been identified in vivo: the 3-iodothyronamine
(T1AM) and the thyronamine (T0AM). These compounds
have been postulated to derive from thyroid hormone (T4)
through deiodination and decarboxylation. T1AM is widely
expressed in various tissues, such as brain, liver, heart, and
blood, and it seems to be the most abundant thyronamine
present in circulation.2
Among several potential receptors, it has been proved that
T1AM binds to TAAR1, a G-protein coupled receptor (GPCR)
that has been identified in specific areas of the central nervous
system and in some peripheral areas. The binding of T1AM to
TAAR1 receptor leads to increase of cAMP levels by the
activation of the adenylate cyclase. Further studies also
highlighted that T1AM interact with other targets such as the
biogenic amines transporters and the apoB100 protein.
Thyronamines, and in particular T1AM, produce different
functional effects although their physiological role still remains
unclear. Among the most significant effects attributed to T1AM
are a hypothermic as well as negative inotropic and
chronotropic cardiac effects. Moreover, endocrine and meta-
bolic effects such as the modulation of insulin secretion, the
inhibition of catecholamines resorption at the neuronal level,
and an increased metabolism of lipids at the expense of that of
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carbohydrates have been also described.3 The wide variety of
functions attributed to T1AM makes this molecule a potentially
useful tool for the treatment of many diseases such as obesity,
neuropsychiatric disorders, and cancer. Unfortunately, TAMs
are rapidly metabolized by different enzyme systems such as
amino-oxidase (MAO, SSAO), deiodinase (DIO3), sulfotrans-
ferase (SULT1A1 and SULT1A3), N-acetyltransferase, and
glucuronidase. The action of these enzymes is a limit to their
therapeutic use. Consequently, the great therapeutic potential
as well as the lack of new useful tools to elucidate the
physiological function of T1AM have pushed medicinal
chemists to develop new synthetic analogues of T1AM.
Recently, with the aim of increasing the number of selective
ligands for TAAR1 receptor and provide new tools to facilitate
the understanding of the physiological functions of this
receptor, we reported the design and synthesis of a new class
of thyronamine-like compounds with a diphenylmethane
scaffold, which proved to be synthetically more accessible
than endogenous T1AM and T0AM.4,5 Within the small series
of analogues previously synthesized, SG1 and SG2 were found
to activate mouse TAAR1 receptor (mTAAR1) with a potency
comparable to the corresponding endogenous ligands4 (Figure
1). In particular, SG2, the analogue of T1AM, showed an EC50
= 240 nM comparable to T1AM (EC50 = 189 nM). To expand
the SAR study for this new class of compounds, in the present
work we describe the design and synthesis of compounds 1−16
obtained by introducing specific structural changes at key
points of our lead compound SG2 skeleton. The structural
optimization process of the new thyronamine-like compounds
was based on molecular docking studies that highlighted the
main differences in the interaction between the endogenous
ligand T1AM or the synthetic analogue SG2 with the mTAAR1
receptor binding site. The newly designed compounds were
first screened in vitro for mTAAR1 activation. Five compounds
(1, 2, 4, 7, and 8) showed a higher potency than the lead
molecule SG2, as well as the endogenous ligand T1AM, with 1
and 2 being the most potent of the new series. These
compounds were then evaluated both in vitro and in vivo to
characterize their ability to modulate plasma glucose levels.
■ RESULTS
Design of New Thyronamine-Like Analogues. In our
previous work, we explored the pharmacological profile of a
new series of T1AM diphenylmethane analogues, and among
these compounds SG1 and SG2 were found to be a good mimic
of the corresponding endogenous ligands T0AM and T1AM,4
respectively. In addition, a docking study was performed to
investigate the main differences between T1AM and the lead
diphenylmethane analogue SG2 on mTAAR1 receptor binding.
According to this study, T1AM appears to be highly stabilized
in the binding site through the formation of two H-bonds
between the protonated amino group of the ethylamine side
chain and aspartic acid 102 (D102) and tyrosine 291 (Y291).
Furthermore, T1AM established an additional H-bond between
the hydroxyl-group on the outer ring and arginine 82 (R82),
while no significant amino acid interactions were observed for
the biaryl-ethereal oxygen of T1AM. Notably, the SG2
derivative appeared to share most of the main mTAAR1/
T1AM interactions.4 Interestingly, the replacement of the
Figure 1. Structure of T1AM and the lead molecules SG1 and SG2
with a diphenylmethane molecular scaffold.
Scheme 1a
aReagents and conditions: (a) SOCl2, CHCl3, rt, 2 h; (b) NaCN, H2O/CH3CN, mw; (c) LiAlH4, AlCl3, THF, reflux, 12 h; (d) Ac2O/NaHCO3, rt, 1
h; (e) H2, Pd-C, AcOH, 12 h; (f) NaNO2, H2SO4, H2O, 100 °C, 1 h.
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hydroxyl group on the T1AM outer ring with an amino group,
as in SG2, allowed the formation of a cation−π interaction,
while no H-bonds to the R82 backbone oxygen atom were
observed. Conceivably, the oxygen atom in the SG2-inner ring
side chain may induce a shift of the molecule within the binding
site, thus preventing the H-bond formation with R82. To
expand the SAR study for this new class of thyronamine
analogues, we performed specific structural changes at key
points of the SG2-molecular scaffold. Initially, to restore the H-
bond with R82, the oxo-ethylamino side chain of SG2 was
replaced with an ethylamine one (1−6). Among these new
compounds, analogue 2 was synthesized to evaluate the effects
induced by the recovery of the phenolic function as in T1AM.
Additionally, to gain further insights on how the pattern of
substitutions modulate the SG-analogues potency as mTAAR1
agonists, we investigated the following structure modifications:
(a) the introduction of small alkyl substituents (Me, i-Pr) on
both outer and inner rings (4, 6−10), (b) the removal of the
methylene bridge, producing the diaryl analogues 5 and 6, (c)
the introduction of a biguanide moiety at the oxy-alkyl side
chain (15, 16), and finally (d) mono- and bis-N-acetylation (3,
9−15). This last chemical modification has been suggested by a
recent study conducted by Hoefig et al.,6 showing that O-acetyl
and N-acetyl derivatives of T1AM may be found in white
adipose tissue and liver endogenous cells. Notably, N-Ac-
T1AM was also found to be an endogenous cardioactive
metabolite.6 On the basis of these findings, the corresponding
mono- and bis-N-acetylated analogues of SG1 and SG2 lead
compounds (i.e., 11, 12 and 13, 14, respectively) as well as the
new acetylated products namely 3, 9, 10, and 15, were
synthesized.
Synthesis. The derivatives 1−6 in which the oxo-ethyl-
amino side chain of SG2 has been replaced with the ethylamine
one have been synthesized as reported in Scheme 1. Briefly, the
products 17−20 obtained by the palladium(0)-catalyzed
Suzuki−Miyaura cross-coupling reaction of the trifluoroborate
salt or boronic acid with the appropriate benzyl bromide,4
reacted with SOCl2 to give benzyl chloride 21−24.
Subsequently, the nucleophilic substitution with NaCN
afforded the compound 25−28 with high yields. As previously
described,4 reduction of nitrile derivative with LiAlH4 in the
presence of a Lewis’s acid afforded the diamine derivatives 1,
4−6. Then, the treatment of 1 with a mixture of Ac2O/
NaHCO3 provided the acetylanilide 3 (Scheme 1a).
Compound 2 was obtained starting from the acetonitrile
derivative 25. Reduction of the nitro-group with H2 in the
presence of 10% Pd-C afforded the aniline 29. The subsequent
hydrolysis of the diazonium salt obtained by reaction of 29 with
NaNO2/H2SO4 afforded the final product 2 (Scheme 1b).
The Suzuki−Miyaura cross-coupling reaction of the 2,6-
dimethyl-4-methoxy-boronic acid with the 4-nitrobenzyl bro-
mide gave 31, which was demethylated with BBr3 at 0 °C,
Scheme 2a
aReagents and conditions: (a) 4-nitrobenzyl bromide, K2CO3, PdCl2, acetone/H2O, rt, 72 h; (b) BBr3, DCM, 0 °C, 1 h; (c) BrCH2CN, DMF,
Cs2CO3, rt, 30 h; (d) LiAlH4, AlCl3, THF, reflux, 12 h.
Scheme 3a
aReagents and conditions: (a) PdCl2 dppf, Cs2CO3, H2O/dioxane, 95 °C, 24 h; (b) SOCl2, CHCl3, rt, 2 h; (c) NaCN, H2O/CH3CN, mw; ()
LiAlH4, AlCl3, THF, reflux, 12 h; (e) Ac2O/NaHCO3, rt,1 h.
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affording to phenol 32. The subsequent reaction of α-bromide-
acetonitrile with 32 followed by reduction to the corresponding
diamine-derivative gave the superior homologue of SG2 (7)
(Scheme 2).
Derivative 8−10 substituted with an i-Pr group in the outer
ring and with a small N-alkyl (8) or N-acetyl group (9, 10)
were synthesized starting from the cross coupling reaction of N-
(4-(bromomethyl)-2-isopropylphenyl)acetamide (34) (see
Supporting Information, Scheme S1) and the (4-(hydrox-
ymethyl)-2-methylphenyl)fluoroboronate salt (Scheme 3). The
tandem reactions with SOCl2 and NaCN gave the nitrile
derivative 37 with high yields. Subsequent reduction with
LiAlH4/AlCl3 afforded the product 8, which was then reacted
with Ac2O in the presence of NaHCO3 in a ratio of 1:1 or 1:2
to give 9 and 10, respectively.
Concerning the synthesis of the mono- and N-diacetylated
derivatives 11−14 and the biguanide analogue of SG2 (15 and
16), the synthetic pathway as well as the procedures are
reported in Supporting Information (Scheme S2).
Receptor Activation. mTAAR1 is coupled to stimulatory
G protein and thus induces cAMP production in HEK293 upon
agonist exposure. We measured the activity of the new
compounds using a BRET-based assay as previously reported
by us.4,7 The standard TAAR1 agonist β-PEA was used as
reference compound (EC50 = 138 nM).
Initially, all 1−16 compounds were tested at a screening
concentration of 10 μM. Then, for the compounds that were
found to be active, a dose−response curve was performed to
calculate their corresponding EC50 values (Figure 2). As shown
in Table 1, five compounds, namely 1,2, 4, 7, and 8, appeared
to be more potent than the lead compound SG2 as well as
T1AM. All of them showed to be full agonists (efficacy =
100%). In particular, the more effective structure modifications
resulted from the replacement of oxy-ethylamino side chain of
SG2 with the ethylamino one (1) and the concomitant
replacement of the amino group of the outer ring with the
hydroxyl moiety (2). Moreover, the addition of small alkyl
groups in the inner ring of SG2 (7), as well as in the outer ring
of the N-ethyl analogue of 1 (8), turned out to be successful,
thus obtaining new compounds with a potency 2-fold higher
than the lead compound SG2 (Table 2).
Docking Study. In our previous work, we investigated
T1AM and a series of T1AM analogues whose potency profile
proved to be highly related to the presence of a proper basic
feature linked to an aromatic core.4 Indeed, our molecular
modeling studies pointed out the relevance of a key salt bridge
between the protonated amine group of SG1 and SG2 lead
compounds and the highly conserved residue D102, together
with a number of π−π stacking and cation−π contacts with the
Figure 2. Dose−response curves of the most active SG2-analogues. All the compounds are full agonists (efficacy = 100%).
Table 1. Activity of the New Diphenylmethane Derivatives
1−6 and 8−10 Using BRET-Based Assay in mTAAR1
Transfected HEK 293 Cellsa
compd X n R R1 R2 Y
mTAAR1 EC50
(nM)
1 NH2 1 Me H H NH2 119
2 OH 1 Me H H NH2 98
3 NHAc 1 Me H H NH2 3100
4 NH2 1 Me Me H NH2 158
5 NH2 0 Me H H NH2 1180
6 NH2 0 Me Me H NH2 633
8 NHEt 1 Me H i-Pr NH2 102
9 AcNEt 1 Me H i-Pr NH2 440
10 AcNEt 1 Me H i-Pr NHAc >10000
aThe EC50 values are expressed in nM.
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surrounding amino acids, as we previously detected in other
series of TAAR1 ligands.8,9
These findings were supported by further homology
modeling and docking studies we performed within the murine
and human TAAR1 and TAAR5 receptors with respect to
T1AM ligand
10 and were also in accordance with the key role
played by a proper basic feature included in any TAAR1 ligand,
as reported in literature.11 Notably, this information was
definitively validated by the mutagenesis data involving the
D102 residue, reported by Reese.12
To rationalize the pharmacological results and refine the
computational models, in silico docking studies on the most
active compounds (1, 2, 7, and 8) were also performed,
analyzing their interactions with the putative receptor binding
site (see Supporting Information, Table S1).
In agreement with the experimental data, our docking
calculations revealed that the presence of the ethylamine chain
appears to be the most effective choice, in particular within
those series of compounds bearing a mono methyl-substituted
inner ring (1, 2, and 8). On the basis of a comparison with the
prototype T1AM, the most promising newly designed
analogues were overturned within the receptor binding site,
maintaining in any case the key contact with D102 which is
required for TAAR1 agonism (see Supporting Information,
Figure S1).12
Notably, the most effective compounds 1 and 2 were
characterized by a reversed docking mode when compared to
that previously described for SG2.4 Briefly, we originally
highlighted the key role played by the protonated amino group
of the ethyloxyamine side chain of SG2 in H-bonding with
D102 and Y291, while the inner-phenyl group was engaged in
π−π stacking with Y287. On the contrary, 1 (and 2) displayed
one H-bond between the aniline portion in the outer ring (or
the hydroxyl group) and the D102 negatively charged side
chain, while the protonated basic side chain appeared to be
involved in one H-bond and in a salt bridge with T83 and
D284, respectively, as shown in parts a and b of Figure 3,
respectively.
The addition of a methyl group in the inner ring of SG2 led
to a 2-fold increase of potency for 7, with an EC50 of 134 vs 240
nM for SG2. The docking study showed that also 7 takes an
overturned positioning with respect to SG2 in the binding site
of mTAAR1 (Figure 3c). Presumably, the presence of an
additional substituent into the inner ring causes a shift of the
molecule within the binding site, promoting the interaction of
the aniline nitrogen atom in the outer ring with D102 residue
while the side chain’s nitrogen atom interacts with D284.
Finally, the introduction of small alkyl groups into the outer
ring of 1 as in compound 8 did not prevent the interaction
between the nitrogen atom of aniline with D102 residue.
Table 2. Activity of the New Diphenylmethane Derivatives 7 and 11−16 Using BRET-Based Assay in mTAAR1 Transfected
HEK 293 Cellsa
aThe EC50 values are expressed in nM.
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Figure 3. Docking mode of compounds SG2 (C atom cyan) and (a) 1 (C atom deep magenta), (b) 2 (C atom; coral), (c) 7 (C atom; light green),
and (d) 8 (C atom; yellow) at the murine TAAR1 binding site. The most important residues are labeled.
Figure 4. (a) Glucose production in HepG2 cell cultures that were incubated for 4 h in glucose production buffer after adding vehicle (DMSO) or
compounds 1, 2, and T1AM. Results are expressed as mean ± SEM and are normalized to the total cell protein content determined in cell lysates (n
= 3 in each case). (b) Glucose production in HepG2 cell in response to increasing concentrations of compounds 1 (0.1, 1, 10, and 20 μM) and 2
(0.001, 0.01, 0.1, 1, and 10 μM). Results are mean ± SEM and are normalized to the total cell protein content determined in cell lysates. (n = 6 in
each case). *P < 0.05, **P < 0.01, ***P < 0.001 by ANOVA.
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Indeed, the EC50 value of 8 (EC50 = 102 nM) was comparable
to that of 1 (EC50 = 119 nM).
Modulation of Hepatic Glucose Production. The
hyperglycemic effect observed after administration of exoge-
nous T1AM had previously been attributed only to a
modulation of insulin and/or glucagone secretion.13−15
Recently, our study16 showed that in human hepatocarcinoma
cells (HepG2) T1AM treatment directly stimulated glucose
production (EC50 = 0.84 μM) if adequate gluconeogenetic
substrates were provided. Interestingly, the effect of T1AM on
gluconeogenesis displayed a bell-shaped dose−response curve,
suggesting a biphasic effect of T1AM on the modulation of
gluconeogenesis. In the present study, the effects induced by
two of the most potent new mTAAR1 agonists (i.e., 1 and 2)
on gluconeogenesis were assessed. Preliminarily, HepG2 cells
were incubated with each compound at three different doses
(0.1, 1, and 10 μM). By comparison, similar experiments were
performed using T1AM. As shown in Figure 4a, incubation
with 0.1 and 1 μM of compound 2 induced a significant
increase in glucose production (P < 0.01), while a dose of 10
μM induced a decreased stimulation of glucose production. On
the other hand, compound 1 showed a dose-dependent
increase of glucose production, which reached statistical
significance only when compound 1 was used at the highest
dose (10 μM). As shown in Figure 4a, treatment of HepG2
cells with T1AM (0.1, 1, and 10 μM) confirmed the bell-shaped
dose−response curve observed in our previous study.16 To
better define the dose dependence of 1 and 2 effects on glucose
production, additional experiments were carried out using a
wider range of doses for both compounds. As shown in Figure
4b, the EC50 calculated for the effect on gluconeogenesis was in
the submicromolar range for 2, and in the supramicromolar
range for 1.
Modulation of Plasma Glucose Level. As previously
reported by us, thyronamine-like analogues SG1 and SG2
demonstrated the ability to increase plasma glycaemia with a
potency comparable to that of the corresponding endogenous
thyronamine (i.e., T0AM and T1AM).4 Thus, in the present
work, the effects induced by 1 and 2 derivatives on plasma
glucose level were also assessed.
Figure 5 shows that a single low dose (4.0 μg/kg, ip) of 1 or
2 significantly increases plasma glycaemia in CD-1 mice with a
potency comparable to that previously shown by lead
compound SG2.4
■ CONCLUSION
Our ongoing efforts to develop thyronamine-like analogues
synthetically more accessible than endogenous thyronamines
yielded a new class of potent mTAAR1 diphenylmethane
ligands.
A medicinal chemistry optimization combined to docking
studies were used starting from the molecular scaffold of our
recently developed SG-compounds to design the new ligands.
In particular, we investigated: (i) the replacement of the
oxyethylamino side chain of SG2 with an ethylamino one, (ii)
the introduction of small alkyl substituents (Me, i-Pr) on both
outer and inner rings, and (iii) the recovery of the phenolic
function as in T1AM. Overall these chemical modifications
resulted in more potent mTAAR1 agonists when compared to
T1AM, as well as lead compound SG2. Taking into account the
high structure similarity of compounds 1 and 2 with T1AM and
their high affinity for mTAAR1, we further investigated their
ability to modulate glucose levels using both in vitro (human
HepG2 cells) and in vivo (CD1-mice) models. Both
compounds demonstrated potent functional activity. In
conclusion, this paper describes for the first time the successful
outcome of a hit-to-lead optimization process, leading to the
identification of new tools to explore the physiological and
pharmacological functions of TAAR1.
■ EXPERIMENTAL SECTION
Chemistry. General Material and Methods. Melting points were
determined on a Kofler hot-stage apparatus and are uncorrected.
Chemical shifts (δ) are reported in parts per million downfield from
tetramethylsilane and referenced from solvent references; coupling
constants J are reported in hertz. 1H NMR and 13C NMR spectra of all
compounds were obtained with a Bruker TopSpin 3.2 400 MHz
spectrometer. 13C NMR spectra were fully decoupled. The following
abbreviations are used: singlet (s), doublet (d), triplet (t), double−
doublet (dd), and multiplet (m). The elemental compositions of the
compounds agreed to within ±0.4% of the calculated values.
Chromatographic separation was performed on silica gel columns by
flash (Kieselgel 40, 0.040−0.063 mm; Merck) or gravity column
(Kieselgel 60, 0.063−0.200 mm; Merck) chromatography. The ≥95%
purity of the tested compounds was confirmed by combustion analysis.
Reactions were followed by thin-layer chromatography (TLC) on
Merck aluminum silica gel (60 F254) sheets that were visualized under
a UV lamp. The microwave-assisted procedures were carried out with a
CEM Discover LabMate microwave. Evaporation was performed in
vacuo (rotating evaporator). Sodium sulfate was always used as the
drying agent. Commercially available chemicals were purchased from
Sigma-Aldrich.
4-(4-(2-Aminoethyl)-2-methylbenzyl)aniline (1). To a suspension
of LiAlH4 (4.80 mL, 4.80 mmol) in THF was added dropwise a
solution of AlCl3 (639.6 mg, 4.80 mmol) in THF (20 mL), and the
mixture was stirred for 5 min at rt. A solution of 25 (142.0 mg, 0.53
mmol) in THF was added dropwise, and the mixture was heated at
reflux for 12 h. The mixture was cooled to 0 °C with an ice bath and
added dropwise with water and then with 10% aqueous HCl. The
mixture was extracted with diethyl ether, and the aqueous layer was
made alkaline with NaOH 2N and extracted with CHCl3. The organic
phase was separated, washed with brine, dried, filtered, and
concentrated. The crude was purified by conversion in the
corresponding hydrochloride salt. White solid; mp 153−157 °C
(67% yield). 1H NMR (CD3OD): δ 2.21 (s, 3H, CH3), 2.94 (t, 2H, J =
7.8 Hz, CH2), 3.17 (t, 2H, J = 7.8 Hz, CH2), 4.03 (s, 2H, CH2), 7.07−
7.15 (m, 3H, Ar), 7.29 (d, 2H, J = 8.4 Hz, Ar), 7.34 (d, 2H, J = 8.4 Hz,
Ar) ppm. 13C NMR (CD3OD): δ 143.44, 138.48, 138.37, 136.40,
131.89, 131.66, 131.35, 129.71, 127.54, 124.11, 41.99, 39.31, 34.09,
19.70 ppm. Anal. (C16H20N2·HCl) C, H, N. % Calcd: 79.96 (C); 8.39
(H); 11.66 (N). % Found: 79.88 (C); 8.55 (H); 11.42 (N).
Figure 5. Effect of 1 and 2 on plasma glycaemia (mg·L−1) in CD1-
mice. Plasma glucose was measured 15 min after test compound or
vehicle injection (ip) in blood collected from the tail veins of 4 h
starved mice (n = 8 in each group). Results are expressed as means
mean ± SEM. *P < 0.05 vs vehicle. ***P < 0.001 vs vehicle.
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4-(4-(2-Aminoethyl)-2-methylbenzyl)phenol (2). Compound 2
was synthesized from 30 (109 mg, 0.46 mmol), LiAlH4 (4.13 mL,
4.13 mmol), and AlCl3 (550.8 mg, 4.13 mmol) in THF (18 mL)
following the same procedure described above for the preparation of 1.
Yellow solid; mp 138−140 °C (30% yield). 1H NMR (CD3OD): δ
2.18 (s, 3H, CH3), 2.70 (t, 2H, J = 7.2 Hz, CH2), 2.87 (t, 2H, J = 7.2
Hz, CH2), 3.81 (s, 2H, CH2), 6.64 (d, 2H, J = 8.4 Hz, Ar), 6.84 (d, 2H,
J = 8.4 Hz, Ar), 6.94−7.03 (m, 3H, Ar) ppm. 13C NMR (CD3OD): δ
146.29, 139.28, 137.93, 137.82, 131.69, 131.64, 131.10, 130.31, 127.21,
116.88, 54.79, 39.22, 38.30, 19.74 ppm. Anal. (C16H19NO) C, H, N. %
Calcd: 79.63 (C); 7.94 (H); 5.80 (N). % Found: 79.77 (C); 7.81 (H);
5.92 (N).
N-(4-(4-(2-Aminoethyl)-2-methylbenzyl)phenyl)acetamide (3).
To a solution of 1 (50 mg, 0.18 mmol) in saturated NaHCO3
solution (0.06 mL) was added Ac2O (0.02 mL, 0.18 mmol). The
mixture was left stirring at rt for 1 h, and then the mixture was
dissolved in water and extracted with CHCl3. The organic layer was
dried and concentrated under reduced pressure. The crude product
was purified by precipitation from MeOH/Et2O to give 3. White
solid;mp 132−136 °C (60% yield). 1H NMR (CD3OD): δ 2.10 (s,
3H, CH3), 2.20 (s, 3H, COCH3), 2.92 (t, 2H, J = 7.7 Hz, CH2), 3.15
(t, 2H, J = 7.7 Hz, CH2), 3.91 (s, 2H, CH2), 7.04 (d, 2H, J = 8.4 Hz,
Ar), 7.05−7.11 (m, 3H, Ar), 7.34 (d, 2H, J = 8.4 Hz, Ar) ppm. 13C
NMR (CD3OD): δ 171.57, 139.37, 138.31, 137.77, 137.62, 135.91,
131.71, 131.52, 129.93, 127.33, 121.33, 42.01, 39.37, 34.09, 23.77,
19.74 ppm. Anal. (C16H20N2·HCl) C, H, N. % Calcd: 79.96 (C); 8.39
(H); 11.66 (N). % Found: 79.88 (C); 8.55 (H); 11.42 (N).
4-(4-(2-Aminoethyl)-2,6-dimethylbenzyl)aniline (4). Compound 4
was synthesized from 26 (109 mg, 0.46 mmol), LiAlH4 (4.13 mL, 4.13
mmol), and AlCl3 (550.8 mg, 4.13 mmol) in THF (18 mL) following
the same procedure described above for the preparation of 1. The
crude was purified by conversion in the corresponding hydrochloride
salt. White solid; mp 143−145 °C (68% yield). 1H NMR (CD3OD): δ
2.22 (s, 6H, CH3), 2.91 (t, 2H, J = 7.7 Hz, CH2), 3.18 (t, 2H, J = 7.7
Hz, CH2), 4.11 (s, 2H, CH2), 7.01 (s, 2H, Ar), 7.17 (d, 2H, J = 8.6 Hz,
Ar), 7.30 (d, 2H, J = 8.6 Hz, Ar) ppm. 13C NMR (CD3OD): δ 142.77,
138.85, 136.31, 136.14, 130.58, 129.68, 129.61, 124.13, 42.00, 34.98,
34.12, 20.23 ppm. Anal. (C17H22N2·HCl) C, H, N. % Calcd: 80.27
(C); 8.72 (H); 11.01 (N). % Found: 80.40 (C); 8.59 (H); 11.31 (N).
4′-(2-Aminoethyl)-2′-methyl-[1,1′-biphenyl]-4-amine (5). Com-
pound 5 was synthesized from 27 (109 mg, 0.46 mmol), LiAlH4
(4.13 mL, 4.13 mmol), and AlCl3 (550.8 mg, 4.13 mmol) in THF (18
mL) following the same procedure described above for the preparation
of 1. The crude was purified by conversion in the corresponding
hydrochloride salt. White solid; mp 165−167 °C (70% yield). 1H
NMR (CD3OD): δ 2.25 (s, 3H, CH3), 2.99 (t, 2H, J = 7.8 Hz, CH2),
3.22 (t, 2H, J = 7.8 Hz, CH2), 7.19 (d, 2H, J = 1.2 Hz, Ar), 7.25 (s, 1H,
Ar), 7.51−7.46 (m, 4H, Ar) ppm. 13C NMR (CD3OD): δ 144.11,
140.55, 137.72, 137.02, 131.99, 131.21, 130.72, 127.48, 124.08, 41.92,
34.19, 20.43 ppm. Anal. (C15H18N2·HCl) C, H, N. % Calcd: 79.61
(C); 8.02 (H); 12.38 (N). % Found: 80.00 (C); 8.10 (H); 12.22 (N).
4′-(2-Aminoethyl)-2′,6′-dimethyl-[1,1′-biphenyl]-4-amine (6).
Compound 6 was synthesized from 28 (109 mg, 0.46 mmol),
LiAlH4 (4.13 mL, 4.13 mmol), and AlCl3 (550.8 mg, 4.13 mmol) in
THF (18 mL) following the same procedure described above for the
preparation of 1. The crude was purified by conversion to the
corresponding hydrochloride salt. White solid; mp 171−173 °C (73%
yield). 1H NMR (CD3OD): δ 2.00 (s, 3H, CH3), 2.95 (t, 2H, J = 7.8
Hz, CH2), 3.20 (t, 2H, J = 7.8 Hz, CH2), 7.07 (s, 2H, Ar), 7.30 (d, 2H,
J = 8.4 Hz, Ar), 7.53 (d, 2H, J = 8.4 Hz, Ar) ppm. 13C NMR
(CD3OD): δ 143.35, 140.41, 137.50, 137.27, 132.17, 130.72, 128.97,
124.52, 41.98, 34.21, 20.84 ppm. Anal. (C16H20N2·HCl) C, H, N. %
Calcd: 79.96 (C); 8.39 (H); 11.66 (N). % Found: 79.90 (C); 8.49
(H); 11.71 (N).
4-(4-(2-Aminoethoxy)-2,6-dimethylbenzyl)aniline (7). Compound
7 was synthesized from 33 (186.2 mg, 0.66 mmol), LiAlH4 (6.87 mL,
6.87 mmol), and AlCl3 (915.6 mg, 6.87 mmol) in THF (25 mL)
following the same procedure described above for the preparation of 1.
The crude was purified by conversion to the corresponding
hydrochloride salt. White solid; mp 156−158 °C (75% yield). 1H
NMR (CD3OD): δ 2.20 (s, 6H, CH3), 3.37 (t, 2H, J = 5.0 Hz, CH3),
4.07 (s, 2H, CH2), 4.23 (t, 2H, J = 5.0 Hz, CH2), 6.76 (s, 2H, Ar), 7.15
(d, 2H, J = 8.4 Hz, Ar), 7.30 (d, 2H, J = 8.4 Hz, Ar) ppm. 13C NMR
(CD3OD): δ 156.50, 141.82, 138.32, 129.24, 129.09, 128.16, 122.72,
114.04, 63.74, 39.07, 33.21, 19.10 ppm. Anal. (C17H22N2O·HCl) C, H,
N. % Calcd: 75.52 (C); 8.20 (H); 10.36 (N). % Found: 75.60 (C);
8.07 (H); 10.40 (N).
4-(4-(2-Aminoethyl)-2-methylbenzyl)-N-ethyl-2-isopropylaniline
(8). Compound 8 was synthesized from 37 (130.8 mg, 0.41 mmol),
LiAlH4 (1.84 mL, 1.84 mmol), and AlCl3 (244.8 mg, 1.84 mmol) in
THF (17 mL) following the same procedure described above for the
preparation of 1. The crude was purified by conversion in the
corresponding hydrochloride salt. Brown solid; mp 148−150 °C (67%
yield). 1H NMR (CD3OD): δ 1.28 (d, 6H, J = 6.8 Hz, CH3), 1.37 (t,
3H, J = 7.2 Hz, CH3), 2.22 (s, 3H, CH3), 2.93 (t, 2H, J = 7.8 Hz,
CH2), 3.05−3.12 (m, 1H, CH), 3.16 (t, 2H, J = 7.8 Hz, CH2), 3.43 (q,
2H, J = 7.2 Hz, CH2), 4.04 (s, 2H, CH2), 7.06−7.14 (m, 4H, Ar), 7.32
(d, 1H, J = 8.4 Hz, Ar), 7.36 (d, 1H, J = 1.6 Hz, Ar) ppm. 13C NMR
(CD3OD): δ 144.42, 143.51, 138.47, 138.36, 136.41, 131.87, 131.56,
131.00, 129.52, 128.88, 127.54, 124.53, 49.90, 41.97, 39.45, 34.11,
28.70, 24.43, 19.72, 11.38 ppm. Anal. (C21H30N2·HCl) C, H, N. %
Calcd: 81.24 (C); 9.74 (H); 9.02 (N). % Found: 81.36 (C); 9.65 (H);
9.11 (N).
N-(4-(4-(2-Aminoethyl)-2-methylbenzyl)-2-isopropylphenyl)-N-
ethylacetamide (9). Compound 9 was synthesized from 8 (45.6 mg,
0.15 mmol), saturated NaHCO3 solution (0.05 mL), and Ac2O (0.01
mL, 0.15 mmol) following the same procedure described above for the
preparation of 3. The crude solid was collected by filtration and
purified by conversion to the corresponding hydrochloride salt. Yellow
solid (30% yield). 1H NMR (CD3OD): δ 1.08−1.20 (m, 9H, CH3,
CH3CH2), 1.73 (s, 3H, COCH3), 2.24 (s, 3H, CH3), 2.90−2.96 (m,
3H, CH2, CH), 3.02−3.07 (m, 1H, CH2), 3.17 (t, 2H, J = 7.4 Hz,
CH2), 4.02 (s, 2H, CH2), 4.11−4.18 (m, 1H, CH2), 6.97−7.05 (m,
2H, Ar), 7.07−7.17 (m, 3H, Ar), 7.27 (s, 1H, Ar) ppm. 13C NMR
(CD3OD): δ 173.03, 146.93, 143.12, 138.91, 138.71, 138.36, 136.21,
131.81, 131.53, 130.08, 128.87, 128.30, 127.47, 45.29, 42.01, 39.67,
34.10, 28.83, 24.48, 24.13, 22.59, 19.77, 12.99 ppm. Anal.
(C23H32N2O·HCl) C, H, N. % Calcd: 78.36 (C); 9.15 (H); 7.95
(N). % Found: 78.45 (C); 9.02 (H); 7.84 (N).
N-(4-(4-(2-Acetamidoethyl)-2-methylbenzyl)-2-isopropylphenyl)-
N-ethylacetamide (10). Compound 10 was synthesized from 8 (45.6
mg, 0.15 mmol), saturated NaHCO3 solution (0.05 mL), and Ac2O
(0.02 mL, 0.30 mmol) following the same procedure described above
for the preparation of 3. The reaction mixture was evaporated and the
crude dissolved in AcOEt and washed twice with water. The
evaporation of the organic collected phases gave final product as a
white oil (20% yield). 1H NMR (CD3OD): δ 1.10−1.20 (m, 9H, CH3,
CH3CH2), 1.73 (s, 3H, COCH3), 1.90 (s, 3H, COCH3), 2.21 (s, 3H,
CH3), 2.74 (t, 2H, J = 7.4 Hz, CH2), 2.90−2.96 (m, 1H, CH), 3.01−
3.09 (m, 1H, CH2), 3.37 (t, 2H, J = 7.4 Hz, CH2), 4.00 (s, 2H, CH2),
4.11−4.20 (m, 1H, CH2), 6.99−7.09 (m, 5H, Ar), 7.25 (d, 1H, J = 1.2
Hz, Ar) ppm. 13C NMR (CD3OD): δ 173.20, 173.08, 146.89, 143.36,
138.82, 138.68, 137.88, 137.74, 131.86, 131.13, 130.06, 128.84, 128.28,
127.48, 45.34, 42.13, 39.71, 36.09, 28.86, 24.50, 24.16, 22.60, 22.52,
19.78, 13.00 ppm. Anal. (C25H34N2O2) C, H, N. % Calcd: 76.10 (C);
8.69 (H); 7.10 (N). % Found: 76.25 (C); 8.53 (H); 7.21 (N).
N-(4-(4-(2-Aminoethoxy)benzyl)phenyl)acetamide (11). Com-
pound 11 was synthesized from SG14 (49.7 mg, 0.20 mmol),
saturated NaHCO3solution (0.07 mL), and Ac2O (0.03 mL, 0.20
mmol) following the same procedure described above for the
preparation of 3. The crude product was purified by precipitation
from MeOH/Et2O to give 11. White solid; mp 132−136 °C (60%
yield). 1H NMR (CD3OD): δ 2.10 (s, 3H, COCH3), 3.34 (t, 2H, J =
5.2 Hz, CH2), 3.87 (s, 2H, CH2), 4.19 (t, 2H, J = 5.2 Hz, CH2), 6.92
(d, 2H, J = 8.8 Hz, Ar), 7.10−7.14 (m, 4H, Ar), 7.42 (d, 2H, J = 8.4
Hz, Ar) ppm. 13C NMR (CD3OD): δ 171.59, 157.83, 138.90, 137.82,
136.02, 130.93, 130.03, 121.40, 115.70, 65.29, 41.30, 40.39, 23.76 ppm.
Anal. (C17H20N2·HCl) C, H, N. % Calcd: 71.81 (C); 7.09 (H); 9.85
(N). % Found: 71.88 (C); 7.15 (H); 9.92 (N).
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N-(2-(4-(4-Acetamidobenzyl)phenoxy)ethyl)acetamide (12).
Compound 12 was synthesized from SG1 (47.0 mg, 0.19 mmol),
saturated NaHCO3 solution (0.14 mL), and Ac2O (0.04 mL, 0.38
mmol) following the same procedure described above for the
preparation of 3. The crude product was purified by precipitation
from MeOH/acetone to give 12. White solid; mp 152−153 °C (60%
yield). 1H NMR (DMSO): δ 2.00 (s, 3H, COCH3), 2.08 (s, 3H,
COCH3), 3.34−3.38 (m, 2H, CH2), 3.79 (s, 2H, CH2), 3.91 (t, 2H, J
= 5.6 Hz, CH2), 6.84 (d, 2H, J = 8.8 Hz, Ar), 7.08−7.10 (m, 4H, Ar),
7.45 (d, 2H, J = 8.8 Hz, Ar), 8.06 (br t, NH2), 9.83 (br s, NH) ppm.
13C NMR (CD3OD): δ 173.59, 171.54, 158.58, 139.08, 137.78, 135.20,
130.82, 130.06, 121.39, 115.59, 67.53, 41.32, 40.26, 23.70, 22.46 ppm..
Anal. (C19H22N2O3·HCl) C, H, N. % Calcd: 69.92 (C); 6.79 (H); 8.58
(N). % Found: 69.88 (C); 6.67 (H); 8.61 (N).
N-(4-(4-(2-Aminoethoxy)-2-methylbenzyl)phenyl)acetamide (13).
Compound 13 was synthesized from SG24 (50.0 mg, 0.19 mmol),
saturated NaHCO3 solution (0.07 mL), and Ac2O (0.02 mL, 0.19
mmol) following the same procedure described above for the
preparation of 3. The crude product was purified by precipitation
from MeOH/Et2O to give 13. White solid; mp 132−136 °C (60%
yield). 1H NMR (CD3OD): δ 2.10 (s, 3H, CH3), 2.19 (s, 3H,
COCH3), 3.34 (t, 2H, J = 5.0 Hz, CH2), 3.89 (s, 2H, CH2), 4.20 (t,
2H, J = 5.0 Hz, CH2), 6.77 (dd, 1H, J = 2.4, 8.4 Hz, Ar), 6.83 (d, 1H, J
= 2.4 Hz, Ar), 7.03 (d, 2H, J = 8.4 Hz, Ar), 7.06 (d, 1H, J = 8.4 Hz,
Ar), 7.41 (d, 2H, J = 8.4 Hz, Ar) ppm. 13C NMR (CD3OD): δ 171.58,
158.00, 139.19, 138.03, 137.67, 133.61, 132.00, 129.79, 121.32, 117.73,
112.83, 65.18, 40.41, 38.93, 23.79, 19.96 ppm. Anal. (C18H22N2O2·
HCl) C, H, N. % Calcd: 72.46 (C); 7.43 (H); 9.39 (N). % Found:
72.58 (C); 7.55 (H); 9.42 (N).
N-(2-(4-(4-Acetamidobenzyl)-3-methylphenoxy)ethyl)acetamide
(14). Compound 14 was synthesized from SG2 (50.0 mg, 0.19 mmol),
saturated NaHCO3 solution (0.14 mL), and Ac2O (0.04 mL, 0.38
mmol) following the same procedure described above for the
preparation of 3. The crude product was purified by precipitation
from MeOH/Et2O to give 14. White solid; mp 139−141 °C (56%
yield). 1H NMR (CD3OD): δ 1.95 (s, 3H, CH3), 2.09 (s, 3H,
COCH3), 2.16 (s, 3H, COCH3), 3.53 (t, 2H, J = 5.6 Hz, CH2), 3.87
(s, 2H, CH2), 4.00 (t, 2H, J = 5.6 Hz, CH2), 6.70 (dd, 1H, J = 2.4, 8.4
Hz, Ar), 6.74 (d, 1H, J = 2.4 Hz, Ar), 6.99−7.03 (m, 3H, Ar), 7.41 (d,
2H, J = 8.4 Hz, Ar) ppm. 13C NMR (CD3OD): δ 173.60, 171.53,
158.78, 139.01, 138.27, 137.66, 132.85, 131.94, 129.83, 121.32, 117.66,
112.72, 67.42, 40.30, 38.98, 23.70, 22.47, 19.96 ppm. Anal.
(C20H24N2O3·HCl) C, H, N. % Calcd: 70.56 (C); 7.11 (H); 8.23
(N). % Found: 70.43 (C); 7.05 (H); 8.22 (N).
N-(4-(4-(2-(3-Carbamimidoylguanidino)ethoxy)-2-methyl-
benzyl)phenyl)acetamide (15). A mixture of 13 (32.3 mg, 0.16
mmol) and dicyandiamide (13.5 mg, 0.16 mmol) was heated to 160
°C for 100 min. The reaction mixture initially melts, then resolidifies.
The reaction was cooled to room temperature. The crude product was
purified by crystallization from EtOH/Et2O. Brown oil (52% yield).
1H NMR (CD3OD): δ 2.09 (s, 3H, CH3), 2.15 (s, 3H, COCH3), 3.60
(t, 2H, J = 5.2 Hz, CH2), 3.86 (s, 2H, CH2), 4.05 (t, 2H, J = 5.2 Hz,
CH2), 6.65−6.77 (m, 3H, Ar), 7.01 (d, 2H, J = 8.0 Hz, Ar), 7.41 (d,
2H, J = 8.0 Hz, Ar) ppm. 13C NMR (CD3OD): δ 171.60, 162.12,
161.01, 158.56, 139.04, 138.20, 137.63, 133.00, 131.94, 129.80, 121.34,
117.63, 112.73, 67.55, 42.15, 38.94, 23.74, 19.97 ppm. Anal.
(C20H26N6O2) C, H, N. % Calcd: 62.81 (C); 6.85 (H); 21.97 (N).
% Found: 62.95 (C); 6.73 (H); 21.76 (N).
4-(4-(2-(3-Carbamimidoylguanidino)ethoxy)-2-methylbenzyl)-
aniline (16). To a solution of the amide 15 (0.57 mmol) in MeOH
was added dropwise an aqueous solution of HCl 1N (0.2 mL); the
resulting solution was refluxed for 2 h, and then, after cooling, the
solvent was evaporated. The residue was purified by precipitation from
EtOH/Et2O. Brown oil (60% yield).
1H NMR (CD3OD): δ 2.17 (s,
3H, CH3), 3.79 (t, 2H, J = 4.8 Hz, CH2), 3.99 (s, 2H, CH2), 4.21 (t,
2H, J = 4.8 Hz, CH2), 6.79 (dd, 1H, J = 2.6, 8.2, Ar), 6.83 (d, 1H, J =
2.6 Hz, Ar), 7.08 (d, 1H, J = 8.2 Hz, Ar), 7.26 (d, 2H, J = 8.6 Hz, Ar),
7.32 (d, 2H, J = 8.6 Hz, Ar) ppm. Anal. (C18H24N6O) C, H, N. %
Calcd: 63.51 (C); 7.11 (H); 24.69 (N). % Found: 63.72 (C); 7.05
(H); 24.53 (N).
4-(Chloromethyl)-2-methyl-1-(4-nitrobenzyl)benzene (21). To a
solution of alcohol 17 (96.0 mg, 0.35 mmol) in CHCl3 at 0 °C was
added SOCl2 (3.50 mmol, 0.25 mL). The reaction mixture was stirred
for 2 h at room temperature, and then the solvent was evaporated. The
residue was dissolved in H2O and alkalized with NaOH 1N, and the
aqueous layer was extracted with DCM. The organic phase was dried,
and the solvent was evaporated to give the corresponding crude 21,
which was used without further purification. Yellow oil (80% yield).
1H NMR (CDCl3): δ 2.22 (s, 3H, CH3), 4.08 (s, 2H, CH2), 4.57 (s,
2H, CH2), 7.09 (d, 1H, J = 7.6 Hz, Ar), 7.19−7.24 (m, 2H, Ar), 7.26
(d, 2H, J = 7.4 Hz, Ar), 8.13 (d, 2H, J = 7.4 Hz, Ar) ppm. Anal.
(C15H14ClNO2) C, H, N. % Calcd: 65.34 (C); 5.12 (H); 5.08 (N). %
Found: 65.52 (C); 5.03 (H); 5.24 (N).
5-(Chloromethyl)-1,3-dimethyl-2-(4-nitrobenzyl)benzene (22).
Compound 22 was synthesized from 18 (224 mg, 0.87 mmol) and
SOCl2 (0.63 mL, 8.70 mmol) in CHCl3 (25 mL) following the same
procedure described above for the preparation of 21. The crude was
used without further purification. White oil (76% yield). 1H NMR
(CDCl3): δ 2.22 (s, 6H, CH3), 4.14 (s, 2H, CH2), 4.56 (s, 2H, CH2),
7.13 (s, 2H, Ar), 7.15 (d, 2H, J = 8.5 Hz Ar), 8.11 (d, 2H, J = 8.5 Hz
Ar) ppm. Anal. (C16H16ClNO2) C, H, N. % Calcd: 66.32 (C); 5.57
(H); 4.83 (N). % Found: 66.49 (C); 5.59 (H); 5.11 (N).
4-(Chloromethyl)-2-methyl-4′-nitro-1,1′-biphenyl (23). Com-
pound 23 was synthesized from 19 (125 mg, 0.51 mmol) and
SOCl2 (0.37 mL, 5.10 mmol) in CHCl3 (25 mL) following the same
procedure described above for the preparation of 21. The crude was
used without further purification. Yellow oil (83% yield). 1H NMR
(CDCl3): δ 2.27 (s, 3H, CH3), 4.61 (s, 2H, CH2), 7.21 (d, 2H, J = 7.8
Hz, Ar), 7.31 (d, 1H, J = 7.8 Hz, Ar), 7.34 (s, 1H, Ar), 7.48 (d, 2H, J =
8.8 Hz, Ar), 8.29 (d, 2H, J = 8.8 Hz Ar) ppm. Anal. (C14H12ClNO2) C,
H, N. % Calcd: 64.25 (C); 4.62 (H); 5.35 (N). % Found: 63.91 (C);
4.68 (H); 5.40 (N).
4-(Chloromethyl)-2,6-dimethyl-4′-nitro-1,1′-biphenyl (24). Com-
pound 24 was synthesized from 20 (134 mg, 0.52 mmol) and SOCl2
(0.38 mL, 5.20 mmol) in CHCl3 (25 mL) following the same
procedure described above for the preparation of 21. The crude was
used without further purification. White oil (81% yield). 1H NMR
(CDCl3): δ 2.02 (s, 6H, CH3), 4.58 (s, 2H, CH2), 7.17 (s, 2H, Ar),
7.33 (d, 2H, J = 8.8 Hz Ar), 8.31 (d, 2H, J = 8.8 Hz Ar) ppm. Anal.
(C15H14ClNO2) C, H, N. % Calcd: 65.34 (C); 5.12 (H); 5.08 (N). %
Found: 65.40 (C); 5.59 (H); 5.31 (N).
2-(4-(4-Aminobenzyl)-3-methylphenyl)acetonitrile (25). To a
solution of chloro compound 21 (78.0 mg, 0.46 mmol) in CH3CN
(0.62 mL) was added NaCN (45.1 mg, 0.92 mmol) in H2O (0.21
mL). The mixture was submitted to microwave irradiation (150W, 100
°C, 20 min). After cooling, the solution was extracted with DCM. The
organic phase was dried and evaporated to dryness. Yellow oil (86%
yield). 1H NMR (CDCl3): δ 2.22 (s, 3H, CH3), 3.71 (s, 2H, CH2),
4.07 (s, 2H, CH2), 7.09−7.18 (m, 3H, Ar), 7.25 (d, 2H, J = 8.6 Hz,
Ar), 8.13 (d, 2H, J = 8.6 Hz, Ar) ppm. Anal. (C16H14N2O2) C, H, N. %
Calcd: 72.16 (C); 5.30 (H); 10.52 (N). % Found: 72.34 (C); 5.02
(H); 10.65 (N).
2-(3,5-Dimethyl-4-(4-nitrobenzyl)phenyl)acetonitrile (26). Com-
pound 26 was synthesized from 22 (193 mg, 0.70 mmol) and NaCN
(68.5 mg, 1.40 mmol) in CH3CN/H2O (0.94 mL/0.32 mL) following
the same procedure described above for the preparation of 25. The
crude was used without further purification. White oil (70% yield). 1H
NMR (CDCl3): δ 2.22 (s, 6H, CH3), 3.70 (s, 2H, CH2), 4.13 (s, 2H,
CH2), 7.06 (s, 2H, Ar), 7.14 (d, 2H, J = 8.6 Hz Ar), 8.11 (d, 2H, J =
8.6 Hz Ar) ppm. Anal. (C17H16N2O2) C, H, N. % Calcd: 72.84 (C);
5.75 (H); 9.99 (N). % Found: 72.60 (C); 5.60 (H); 10.02 (N).
2-(2-Methyl-4′-nitro-[1,1′-biphenyl]-4-yl)acetonitrile (27). Com-
pound 27 was synthesized from 23 (95.0 mg, 0.61 mmol) and NaCN
(59.8 mg, 1.22 mmol) in CH3CN/H2O (0.82 mL/0.30 mL) following
the same procedure described above for the preparation of 25. The
crude was used without further purification. Yellow oil (86% yield). 1H
NMR (CDCl3): δ 2.28 (s, 3H, CH3), 3.78 (s, 2H, CH2), 7.21−7.31
(m, 3H, Ar), 7.47 (d, 2H, J = 7.0 Hz, Ar), 8.29 (d, 2H, J = 7.0 Hz Ar)
ppm. Anal. (C15H12N2O2) C, H, N. % Calcd: 71.42 (C); 4.79 (H);
11.10 (N). % Found: 71.41 (C); 4.80 (H); 11.15 (N).
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2-(2,6-Dimethyl-4′-nitro-[1,1′-biphenyl]-4-yl)acetonitrile (28).
Compound 28 was synthesized from 24 (101 mg, 0.36 mmol) and
NaCN (35.3 mg, 0.72 mmol) in CH3CN/H2O (0.49 mL/0.16 mL)
following the same procedure described above for the preparation of
25. The crude was used without further purification. Pale yellow oil
(81% yield). 1H NMR (CDCl3): δ 2.02 (s, 6H, CH3), 3.73 (s, 2H,
CH2), 7.10 (s, 2H, Ar), 7.32 (d, 2H, J = 8.6 Hz Ar), 8.31 (d, 2H, J =
8.6 Hz Ar) ppm. Anal. (C16H14N2O2) C, H, N. % Calcd: 72.16 (C);
5.30 (H); 10.52 (N). % Found: 72.40 (C); 5.59 (H); 10.31 (N).
2-(4-(4-Aminobenzyl)-3-methylphenyl)acetonitrile (29). A solu-
tion of 25 (136 mg, 0.5 mmol) in AcOH (0.5 mL) was hydrogenated
in the presence of 10% Pd-C (28.3 mg), for 12 h. Then the catalyst
was filtered off, and the solvent was removed to dryness to give a crude
product that was used in the subsequent step without any further
purification. Yellow oil (80% yield). 1H NMR (CDCl3) δ: 2.24 (s, 3H,
CH3), 3.68 (s, 2H, CH2), 3.85 (s, 2H, CH2), 6.61 (d, 2H, J = 8.4 Hz,
Ar), 6.88 (d, 2H, J = 8.4 Hz, Ar), 7.06−7.12 (m, 3H, Ar) ppm. Anal.
(C16H16N2) C, H, N. % Calcd: 81.32 (C); 6.82 (H); 11.85 (N). %
Found: 81.45 (C); 6.73 (H); 11.98 (N).
2-(4-(4-Hydroxybenzyl)-3-methylphenyl)acetonitrile (30). To a
mixture of aniline derivative 29 (63.0 mg, 0.26 mmol) in H2O was
added dropwise with H2SO4conc (0.06 mL), and the mixture was stirred
at room temperature for 20 min. Then a solution NaNO2 (17.9 mg,
0.26 mmol) in H2O (0.19 mL) was added dropwise to the reaction
mixture. The resulting solution was stirred for 1 h at 100 °C. The
mixture was cooled to room temperature, and the residue diluted with
AcOEt and washed with brine. The collected organic layers were dried
and evaporated to give compound 30 that was directly used in the next
step. Yellow oil (60% yield). 1H NMR (CDCl3) δ: 2.22 (s, 3H, CH3),
3.84 (s, 2H, CH2), 4.06 (s, 2H, CH2), 7.14−7.19 (m, 3H, Ar), 7.27−
7.33 (m, 4H, Ar) ppm. Anal. (C16H15NO) C, H, N. % Calcd: 80.98
(C); 6.37 (H); 5.90 (N). % Found: 80.72 (C); 6.51 (H); 5.84 (N).
5-Methoxy-1,3-dimethyl-2-(4-nitrobenzyl)benzene (31). To a
solution of 4-methoxy-2,6-dimethylphenylboronic acid (473 mg, 2.63
mmol) in acetone/H2O 1:1 (4 mL) was added, under nitrogen flux, p-
nitrobenzyl bromide (569 mg, 2.63 mmol), K2CO3 (1.24 g, 6.58
mmol), and a catalytic amount of PdCl2. The resulting mixture was
stirred at rt for 62 h in a sealed vial. The crude mixture was evaporated
and then diluted with water and extracted with Et2O. The organic
phase was dried over sodium sulfate and concentrated under vacuum.
The crude residue was purified by column chromatography petroleum
ether/AcOEt (99:1), affording 31. Yellow oil. (49% yield). 1H NMR
(CDCl3): δ 2.19 (s, 6H, CH3), 3.80 (s, 3H, OCH3), 4.08 (s, 2H, CH2),
6.65 (s, 2H, Ar), 7.16 (d, 2H, J = 8.8 Hz, Ar), 8.09 (d, 2H, J = 8.8 Hz,
Ar) ppm. Anal. (C16H17NO3) C, H, N. % Calcd: 70.83 (C); 6.32 (H);
5.16 (N). % Found: 71.01 (C); 6.12 (H); 5.00 (N).
3,5-Dimethyl-4-(4-nitrobenzyl)phenol (32). A solution of 31 (0.39
mmol) in anhydrous DCM (1.5 mL) was cooled to −78 °C and
treated dropwise with a solution of BBr3 in DCM (3.94 mL, 1.24
mmol); the resulting solution was stirred at the same temperature for 5
min and at 0 °C for 1 h. The mixture was then diluted with water and
extracted with DCM. Organic phase was dried and evaporated to give
the product 32. Pale-yellow oil (64% yield). 1H NMR (CDCl3): δ 2.16
(s, 6H, CH3), 4.06 (s, 2H, CH2), 6.59 (s, 2H, Ar), 7.16 (d, 2H, J = 8.8
Hz, Ar), 8.10 (d, 2H, J = 8.8 Hz, Ar) ppm. Anal. (C15H15NO3) C, H,
N. % Calcd: 70.02 (C); 5.88 (H); 5.44 (N). % Found: 70.00 (C); 5.91
(H); 5.63 (N).
2-(3,5-Dimethyl-4-(4-nitrobenzyl)phenoxy)acetonitrile (33). To a
mixture of cesium carbonate (725 mg, 2.22 mmol) and phenol
derivative 32 (0.44 mmol) in 50 mL of DMF was added BrCH2CN
(0.03 mL, 0.44 mmol). The reaction mixture was stirred for 30 min at
rt, poured into 100 mL of cold HCl 1N, and extracted with AcOEt.
The organic phase was dried and evaporated to give the product 33.
White oil (98% yield). 1H NMR (CDCl3): δ 2.22 (s, 6H, CH3), 4.10
(s, 2H, CH2), 4.77 (s, 2H, CH2CN), 6.73 (s, 2H, Ar), 7.15 (d, 2H, J =
8.8, Ar), 8.11 (d, 2H, J = 8.8 Hz, Ar) ppm. Anal. (C17H16N2O3) C, H,
N. % Calcd: 68.91 (C); 5.44 (H); 9.45 (N). % Found: 68.65 (C); 5.52
(H); 9.65 (N)
N-(4-(4-(Hydroxymethyl)-2-methylbenzyl)-2-isopropylphenyl)-
acetamide (35). To a solution of trifluoro(4-(hydroxymethyl)-2-
methylphenyl)borane salt (509 mg, 2.38 mmol) in dioxane/H2O 9:1
(4 mL) was added, under nitrogen atmosphere, N-(4-(bromomethyl)-
2-isopropylphenyl)acetamide 34 (513 mg, 2.38 mmol), cesium
carbonate (2.30 g, 7.1 mmol), and PdCl2dppf (34.8 mg, 0.05
mmol). The resulting mixture was stirred at 95 °C for 24 h in a
sealed vial. The crude mixture was evaporated and then diluted with
water and extracted with DCM. The organic phase was dried over
sodium sulfate and the solvent removed. The crude product was
chromatographed on a silica gel column, eluting with petroleum ether/
AcOEt (9:1). Brown oil (50% yield). 1H NMR (CDCl3): δ δ 1.20 (d,
6H, J = 6.8 Hz, CH3), 2.19 (s, 3H, CH3), 2.26 (s, 3H, CH3CO), 2.96−
3.03 (m, 1H, CH), 3.94 (s, 2H, CH2), 4.65 (s, 2H, CH2), 6.90 (dd,
1H, J = 1.6, 8.0 Hz, Ar), 7.05−7.09 (m, 2H, Ar), 7.13 (d, 1H, J = 8.0
Hz, Ar), 7.17 (s, 1H, Ar), 7.47 (d, 1H, J = 8.0 Hz) ppm. Anal.
(C20H25NO2) C, H, N. % Calcd: 77.14 (C); 8.09 (H); 4.50 (N). %
Found: 77.39 (C); 8.21 (H); 4.64 (N).
N-(4-(4-Chloromethyl)-2-methylbenzyl)-2-isopropylphenyl)-
acetamide (36). Compound 36 was synthesized from 35 (208 mg,
0.67 mmol) and SOCl2 (0.49 mL, 6.70 mmol) in CHCl3 (25 mL)
following the same procedure described above for the preparation of
21. The crude was used without any further purification. Brown oil
(70% yield). 1H NMR (CDCl3): δ 1.20 (d, 6H, J = 6.8 Hz, CH3), 2.20
(s, 3H, CH3), 2.26 (s, 3H, CH3CO), 2.96−3.03 (m, 1H, CH), 3.93 (s,
2H, CH2), 4.57 (s, 2H, CH2), 6.90 (d, 1H, J = 6.0 Hz, Ar), 7.02−7.09
(m, 2H, Ar), 7.15 (d, 1H, J = 8.4 Hz, Ar), 7.19 (s, 1H, Ar), 7.48 (d,
1H, J = 8.4 Hz) ppm. Anal. (C20H24ClNO) C, H, N. % Calcd: 72.82
(C); 7.33 (H); 4.25 (N). % Found: 72.61 (C); 7.42 (H); 4.13 (N).
N-(4-(4-(Cyanomethyl)-2-methylbenzyl)-2-isopropylphenyl)-
acetamide (37). Compound 37 was synthesized from 36 (152 mg,
0.46 mmol) and NaCN (45.3 mg, 0.92 mmol) in CH3CN/H2O (1.86
mL/0.63 mL) following the same procedure described above for the
preparation of 25. The crude was used without any further purification.
Yellow oil (88% yield). 1H NMR (CDCl3): δ 1.20 (d, 6H, J = 6.8 Hz,
CH3), 2.19 (s, 3H, CH3), 2.25 (s, 3H,CH3CO), 2.96−3.03 (m, 1H,
CH), 3.70 (s, 2H, CH2), 3.93 (s, 2H, CH2), 6.89 (d, 1H, J = 8.0 Hz,
Ar), 7.03−7.09 (m, 3H, Ar), 7.12 (s, 1H, Ar), 7.48 (d, 1H, J = 8.0 Hz,
Ar) ppm. Anal. (C21H24N2O) C, H, N. % Calcd: 78.71 (C); 7.55 (H);
8.74 (N). % Found: 78.85 (C); 7.41 (H); 8.90 (N).
Molecular Modeling. All compounds were built, parametrized
(Gasteiger−Huckel method), and energy minimized within MOE
using MMFF94 force field [MOE: Chemical Computing Group Inc.
Montreal. H3A2R7 Canada. http://www.chemcomp.comp]. For all
compounds, the protonated form was considered for the in silico
analyses.
Docking Studies. Docking studies were performed starting from
the in-house homology model of the murine TAAR1 receptor,4 built
on the X-ray structure of the human β2- adrenoreceptor (PDB ID:
3PDS),17 following a protocol we previously discussed exploring the
binding mode of other TAAR1 ligands.8,9 Briefly, the most promising
compounds were docked into the putative ligand binding site by
means of the Surflex docking module implemented in Sybyl-X1.0.18
Surflex-Dock uses an empirically derived scoring function based on
the binding affinities of X-ray protein−ligand complexes. The final
total score listed by Surflex-Dock is a weighted sum of nonlinear
functions involving van der Waals surface distances between the
appropriate pairs of exposed protein and ligand atoms, including
hydrophobic, polar, repulsive, entropic, and solvation and crash terms
represented in terms of a total score conferred to any calculated
conformer. Then, for all the compounds, the best docking geometries
(selected on the basis of the SurFlex scoring functions) were refined
by ligand/receptor complex energy minimization (CHARMM27) by
means of the MOE software.
In Vitro Biological Studies. Reagents. All cell culture reagents
and buffers were from Invitrogen (Carlsbad, CA) and Sigma (St.
Louis, MO). Coelenterazine h was purchased from Promega
(Madison, WI). Plasmid containing the cDNA for the mTAAR1
were generously donated from Hoffman-La Roche. EPAC cAMP
BRET sensor was produced as described.19
Cell Culture and BRET Experiment. Human embryonic kidney
293 cells (HEK293T) were maintained in Dulbecco’s Modified Eagle’s
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Medium supplemented with 10% (v/v) of FBS, 2 mM L-glutamine,
and 0.05 mg/mL of gentamicin at 37 °C in a humidified atmosphere at
95% air and 5% CO2. Transient transfections were performed 24 h
after cells seeding using Lipofectamine 2000 protocol (Invitrogen).
Then 5 μg of mTAAR1 and 4 μg of EPAC for each milliliter of
transfection solution were used for the experiments. For the BRET
experiments, the cells were plated, 6 h after transfection, in poly-D-
lysine coated 96-well microplates at a density of 70000 cells per well in
phenol red free Minimum Essential Medium containing 2% of FBS, 10
mM Hepes, and 2 mM L-glutamine. The cells were then cultured for
an additional 24 h. BRET experiment was conducted as already
described.7 Briefly, for time course experiments, the plate was read
immediately after the addition of the agonist and for approximately 20
min. All the compounds were tested for screening at the initial
concentration of 10 μM. Then, for active compounds, a dose response
was performed in order to calculate the EC50 values. All the
experiments were conducted in the presence of the phosphodiesterase
inhibitor IBMX (Sigma) at the final concentration of 200 μM.
Readings were collected using a Tecan Infinite instrument that allows
the sequential integration of the signals detected in the 465−505 nm
and 515−555 nm windows using filters with the appropriate bandpass
and by using iControl software. The acceptor/donor ratio was
calculated as previously described.20 Curve was fitted using a nonlinear
regression and one site specific binding with GraphPad Prism 5. Data
are representative of 4−5 independent experiments and are expressed
as means ± SEM.
Cell Culture and Glucose Production Evaluation. Human
hepatocellular carcinoma cells (HepG2), obtained from American
Type Culture Collection (Manassas, VA, USA), were cultured in
DMEM supplemented with 10% (v/v) fetal bovine serum, 1 mM
pyruvate, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37 °C
in a humidified atmosphere containing 5% CO2 and subcultured
before confluence. To assess glucose release, HepG2 were seeded into
six-well plates (5 × 105 cells/well) and grown to 80% of confluence
with standard medium. As previously described,9 before treatment cells
were washed twice with PBS and then exposed for 4 h to test
compounds (1 and 2) (0.1, 1, and 10 μM) in 1 mL of DMEM base,
glucose- and phenol red-free, containing 100 U/mL penicillin, 100
mg/mL streptomycin, and 4 mM L-glutamine, supplemented with 2
mM sodium pyruvate and 20 mM sodium lactate (glucose production
buffer) at 37 °C in 5% CO2. Exogenous T1AM (0.1, 1, and 10 μM)
was used as control. Control cells were incubated with supplemented
DMEM containing DMSO (1−2 μL/well). Cell culture medium was
then collected and glucose concentration was measured with a
colorimetric glucose assay kit (GAHK-20, Sigma-Aldrich), following
manufacturer’s instruction. Glucose concentrations were referred to
the total protein content (Bradford 1976) of whole HepG2 lysates.
Results are expressed as the mean ± SEM. Differences between groups
were analyzed by ANOVA. The threshold of statistical significance was
set at P < 0.05. GraphPad Prism version 6.0 for Windows (GraphPad
Software, San Diego, CA, USA) was used for data processing and
statistical analysis.
Measurement of Plasma Glycaemia. This investigation and
animal use procedure complied with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (NIH Publications
no. 80−23, revised 1996) and were approved by the Animal Care
Committee of the Department of Pharmacology, University of
Florence, in compliance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC). All efforts were made
to minimize the number of animals used and their suffering.
Glycaemia was monitored in blood collected from the tail vein of 4
h fasted male mice (CD1 strain, 20−30g, from Envigo, Italy), who had
received 1 and 2 (1.32, 4, and 11 μg·kg−1 ip) or saline (ip) (n = 8 in
each group). Glycaemia was evaluated by a glucorefractometer 15 min
after the ip injections, as described.4 Data are expressed as mean ±
SEM of independent experiments. Statistical analysis was performed
by one-way ANOVA, followed by Student−Newman−Keuls multiple
comparison post hoc test; the threshold of statistical significance was
set at P < 0.05. Data analysis was performed by GraphPad Prism 6.0
statistical program (GraphPad software, San Diego, CA, USA). The
acceptor/donor ratio was calculated as previously described.20 Curve
was fitted using a nonlinear regression and one site specific binding
with GraphPad Prism 5. Data are representative of 4−5 independent
experiments and are expressed as means ± SEM.
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